key: cord-0695288-4qta423p
authors: Poynard, T.; Deckmyn, O.; Rudler, M.; Peta, V.; Ngo, Y.; Vautier, M.; Akhavan, S.; Calvez, V.; Franc, C.; Castille, J. M.; Drane, F.; Sakka, M.; Bonnefont-Rousselot, D.; Lacorte, J. M.; Saadoun, D.; Allenbach, Y.; Benveniste, O.; Gandjbakhch, F.; Mayaux, J.; Lucidarme, O.; Fautrel, B.; Ratziu, V.; Housset, C.; Thabut, D.; Cacoub, P.
title: Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
date: 2020-09-03
journal: nan
DOI: 10.1101/2020.09.01.20186213
sha: 9d2e350e220c7c27e9b2f026a0dbf60cc8b88884
doc_id: 695288
cord_uid: 4qta423p

Background Since 1920, a decrease in serum cholesterol has been identified as a marker of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the main transporter of HDL-cholesterol, to identify the early spread of coronavirus disease 2019 (Covid-19) in the general population and its diagnostic performance for the Covid-19. Methods We compared the daily mean serum apolipoprotein-A1 during the first 34 weeks of 2020 in a population that is routinely followed for a risk of liver fibrosis risk in the USA (212,297 sera) and in France (20,652 sera) in relation to a local increase in confirmed cases, and in comparison to the same period in 2019 (266,976 and 28,452 sera, respectively). We prospectively assessed the sensitivity of this marker in an observational study of 136 consecutive hospitalized cases and retrospectively evaluated its specificity in 7,481 controls representing the general population. Results The mean serum apolipoprotein-A1 levels in the survey populations began decreasing in January 2020, compared to the same period in 2019. This decrease was highly correlated with the daily increase in confirmed Covid-19 cases in the following 34 weeks, both in France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-A1 at the 1.25 g/L cutoff had a sensitivity of 90.6% (95%CI84.2-95.1) and a specificity of 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk ratio of apolipoprotein-A1 for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0;P=0.04). Conclusion Apolipoprotein-A1 could be a sentinel of the pandemic in existing routine surveillance of the general population. NCT01927133, CER-2020-14.

Patrice Cacoub

Order of Authors Secondary Information:

During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous years. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases, including the recovery period.

Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine surveillance of the general population. 

We submit to PlosMedicine an article entitled "Performance of serum apolipoprotein-A1 as a sentinel of Covid-19".

I share my professional life with apolipoprotein-A1 (ApoA1) since 1982, with a prospective cohort of 975 heavy French drinkers, followed by several other cohorts looking for fibrosis biomarkers.

In February 2020, serendipity scenario. Our Hepatology department of Pitié-Salpêtrière, was transformed in a Covid-19 center and I rapidly observed in these severe patients a specific profile of Apo-A1 decrease and Haptoglobin increase, never observed before. The night after, I realize that we have online more than 1 million of ApoA1 and Haptoglobin in the cohorts of patients followed by FibroTest for a risk of liver fibrosis. Therefore, we compared daily the ongoing year 2020 to previous years "Covid-Free". Indeed, there was a highly significant decrease in ApoA1 parallel (2 weeks before) to the confirmed Covid-19 cases. The most original result was that this decrease started few weeks before the incidence of confirmed cases, suggesting that ApoA1 detected infected cases. Furthermore, the liver function biomarkers as well as the Haptoglobin did not change so early.

We observed the normalization of apolipoprotein-A1 in the sera of the French cohort in June, in parallel with the decrease of daily confirmed Covid-19 cases, as well as the plateau in the US cohort. Apolipoprotein-A1 could be a very simple early marker of the Covid-19 pandemic, as suggested in two ongoing surveillance databases, in France and USA with high sensitivity and specificity. It can be done immediately and with low cost in routine surveillance already dosing apolipoprotein-A1, as well as in patients with a clinical suspicion of Covid-19 but with a negative virologic test.

We do think that this article will help clinicians immediately, in the phase of a possible second wave, and epidemiologists for estimating the prevalence of infected subjects in general population, using other surveillance cohorts. Furthermore, our results suggest a potential intestinal transmission without liver signals.

This manuscript has not been presented or is not submitted elsewhere. None of the material concerning the large surveillance databases and the prospective observational cohort has been published or is under consideration for publication elsewhere. According to the context of the pandemic, for assessing the specificity we used controls previously published in large studies of liver diseases. This permitted to have a wide spectrum of false positive risk. These measurements have been all performed on fresh serum collected prospectively and analyzed in the biochemistry unit of Pitié-Salpêtrière Hospital, Paris, France, with the same biochemical methods as for the prospective Covid-19 cases.

The prospective observational study in Covid-19 patients was approved by CER-Sorbonne University IRB, N° 2020-CER-2020-14, with a signed informed consent. Clinical investigation was conducted according to the principles of the Declaration of Helsinki. All authors had access to the study data and reviewed and approved the final manuscript. The components of Fibrotest and Nash-FibroTest were measured in routine in all patients with a risk of liver disease in France. The different databases integrated were used on sera anonymously. All the retrospective database analyses previously published either non-interventional study, without supplementary blood sample, were exempt from institutional review board (IRB) review (ethical committee of 'Comité de Protection des Personnes of Paris, Ile-de-France' FIBROFRANCE project. CPP-IDF-VI, 10-1996-DR-964, DR-2012-222 and USA-NCT01927133).

This project was funded by the European Grant EIT health ProCoP 20879, Patrice Cacoub being the awarded author. All the coauthors have reviewed this manuscript. The data that support the findings of this study are fully available from the corresponding author, upon request.

I have a potential conflict of interest as the inventor of FibroTest, and founder of BioPredictive a spinoff company of Sorbonne University. The patent belongs to the French public organization Assistance Publique Hôpitaux de Paris.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. .

Question: Does serum apolipoprotein-A1 decrease could be a very early biomarker of SARS-88

CoV-2 pandemic? 89

Findings: During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of 90 liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous 91

years. This decrease was highly correlated to and in parallel with the daily increase in confirmed 92

Covid-19 cases, including the recovery period. 93

Meaning: Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine 94

surveillance of the general population. 95 96 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. We compared the daily mean serum apolipoprotein-A1 during the first 30 weeks of 2020 in a 104 population that is routinely followed for a risk of liver fibrosis risk in the USA (183,112 sera) 105 and in France (18,316 sera) in relation to a local increase in confirmed cases, and in comparison 106 to the same period in 2019 (respectively 234,881 and 26,056 sera). We prospectively assessed 107 the sensitivity of this marker in an observational study of 136 consecutive hospitalized cases 108 and retrospectively evaluated its specificity in 7,481 controls representing the general 109 population. 110

The mean serum apolipoprotein-A1 levels in these populations began decreasing in January 112 2020, compared to the same 30 weeks in 2019. This decrease was highly correlated to and in 113 parallel with the daily increase in confirmed Covid-19 cases in the following 30 weeks, in both 114 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. There is an urgent need to detect people in the general population who are at risk of 132 being admitted to the hospital for Covid-19. Although viral nucleic acid testing and chest 133 computed tomography are standard methods for diagnosing Covid-19 in patients with 134 symptoms, these are time consuming. A review reported that there are only three models for 135 predicting hospital admission in the healthy general population, and these are limited by a high 136 risk of bias, and by using proxy outcomes. 1 137

In the meantime, several early detection tests of cytokine burst could be immediately 138 available. In 1920, Harold A. Kipp found that a decrease in serum cholesterol was a marker of 139 severe pneumonia. 2 One hundred years later, a meta-analysis confirmed that levels of high-140 density lipoprotein cholesterol (HDL) and a level below the median of its transporter, 141 apolipoprotein-A1, was associated with a two-fold increase in mortality in patients with severe 142 sepsis (supplementaryFig1,supplementaryTable1). 3 Its decrease seems to occur earlier than 143 the increase in haptoglobin, another marker of sepsis. 4,5 Furthermore, unlike haptoglobin, which 144 is synthesized mainly by the liver, apolipoprotein-A1 is synthesized by both the liver and the 145 intestine. 5 This hypolipidemia begins in Covid-19 patients with mild symptoms. 6,7 Therefore, 146 in the general population, apolipoprotein-A1 might be a sensitive marker of infection in 147 asymptomatic subjects, in those without the pulmonary symptoms of standard Covid-19, or in 148 patients with an intestinal route of infection (supplementaryFile1). 8,9 149 150

Ethics 152

The prospective observational study in Covid-19 patients was approved by CER-Sorbonne 153

University IRB,CER-2020-14, with a signed informed consent. All of the previously published 154 patient analyses from retrospective databases were non-interventional studies, without 155 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20186213 doi: medRxiv preprint supplementary blood samples, and were exempt from a review of the IRB 156 (NCT01927133,supplementaryFile2). The investigation was performed according to the 157 principles of the Declaration of Helsinki. All authors had access to the study data and reviewed 158 and approved the final manuscript. 159

Decrease of apolipoprotein-A1 160

We used three cohorts of sera from subjects at risk of liver fibrosis followed by FibroTest 161 (FibroSure in USA,supplementaryFile2), 10 a large private-laboratories US cohort ("US-162 cohort"), a cohort with an intermediate risk of Covid-19 "(French-cohort") were patients being 163 followed in academic and private-laboratories, and a high-risk cohort which included patients 164 at the Pitié-Salpêtrière hospital Paris, France ("APHP-PSL"). The core temporal analysis 165 compared the first 30 weeks of consecutive anonymous sera 2020 vs. the sera 2019, from these 166 three routinely followed cohorts (supplementaryFile2, supplementaryFig2C). 167

Decrease in apolipoprotein-A1 may be due to direct liver toxicity from SARS-CoV-2, 11 but also 169 to drug-induced liver disease (DILI) caused by medications (supplementaryFile2, 170 supplementaryTable2). We analyzed the kinetics of alpha2-macroglobulin (A2M) a specific 171 marker of liver fibrosis, 10 and of haptoglobin, a sensitive biomarker of severe acute phase, as 172 well in the US-cohort of all the other components, according to non-alcoholic fatty liver disease 173 (NAFLD) sera, or chronic hepatitis C (HCV) sera(supplementaryFile2). 174

The number of confirmed Covid-19 cases in France and in the USA was assessed according to 176 published data from the European Centre for Disease Prevention and Control 177 (https://ourworldindata.org/coronavirus-data) (supplementaryFig2A ,supplementaryFig2B). 178

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. We collected prospective data on apolipoprotein-A1 from and since the first cohort of alcoholic 185 liver disease in 1982, and from the FibroFrance cohort (supplementaryFile2). More recently, 186

we collected six cohorts, which allowed us to retrospectively validate the specificity in a large 187 group of subjects (supplementaryFile2). 

The first primary endpoint was to demonstrate a significant decrease of the mean daily value of 201 apolipoprotein-A1 in the 30 weeks of the year 2020, vs. those of the year 2019. We defined a 202 significant decrease of apolipoprotein-A1 as below 1.25 g/L, the optimal cutoff defined by the 203 highest Youden index (sensitivity + specificity -1) in the severe patients. The daily proportion 204 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. . The other significant differences were, in the French-cohorts, GGT increased during the 243 pandemic peak and returned to previous years' value thereafter (supplementaryFig6), and an 244 increase in ALT in April 2020, in the US-cohort (supplementaryFig7). 245

No significant changes were observed for total cholesterol (supplementaryFig8), triglycerides 246 (supplementaryFig9), fasting glucose (supplementaryFig10), weight (supplementaryFig11) 247 and height (supplementaryFig12). 248

The daily mean number of confirmed Covid-19 cases paralleled about 10 days after the daily 250 proportion of low apolipoprotein-A1 in sera. In USA, the first ten Covid-cases were declared 251 mid-January 2020, when the proportion of low apolipoprotein-A1 had already increase by 252 several percent (fig1E). The first peak of cases (n=50,000) was reached mid-April 253 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. .

(supplementaryFig2B), and the first peak of low apolipoprotein-A1 (37.0%) on April 7 th 254 (fig1E, supplementaryFile2). 255

In France, the first ten Covid-cases were declared first week of March 2020 256 (supplementaryFig2A), when the proportion of low apolipoprotein-A1 started to increase by 257 several percent (fig1C). The first peak of cases (n=7,000) was reached mid-April 258 (supplementaryFig2A), as well as the first peak of low apolipoprotein-A1 (40.0%) on April 259 14 th (fig1C, supplementaryFile2) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. Discussion 294

Our study shows in three cohorts of patients at risk of liver fibrosis, that apolipoprotein-A1 had 295 a highly significant decrease in 2020 vs previous years, and a highly significant negative daily 296 time-related association with the number of Covid-19 cases. Apolipoprotein-A1 decrease had 297 a high sensitivity in prospective hospitalized patients, with a high specificity in retrospective 298 controls, and an independent prognostic value for the survival without transfer to ICU. These 299 results have certain strengths and limitations. 300

The originality of these results was not the decrease in apolipoprotein-A1 during the peak of 302 the pandemic in April, as very low levels of HDL-cholesterol in sera collected in Covid-19 303 were known in severe pneumonia since 1920 (supplementaryTable1). 2 More intriguing was 304 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20186213 doi: medRxiv preprint the very early decrease observed since January 2020 in the USA when the number of Covid-19 305 cases was unknown. The first known Covid-19 patient was detected on 27/12/2019 and 306 19/01/2020 in France and the USA, respectively(supplementaryFile3). The larger sample size 307 of the US surveillance population, compared to the French, allowed detection of a significant 308 1% increase in the proportion of subjects possibly infected using the 1.25 g/L cutoff in January 309 (fig1C), without any inflammatory signal using haptoglobin. We hypothesized that the SARS-310

CoV2 virus influenced the liver or intestinal synthesis of apolipoprotein-A1, in asymptomatic 311 patients or in those with unusual mild symptoms. 312

The decrease of apolipoprotein-A1 in 2020 vs. previous years, as well as the time-related 314 association of apolipoprotein-A1 in 2020 and Covid-19 might be due to numerous confounding 315 factors. In the context of the pandemic we used cohorts of subjects requiring surveillance of 316 liver fibrosis biomarkers which represent at least 30% of the general adult population in the 317 USA and in France. In these cohorts 70% of the subjects had no or minimal fibrosis. The 318 decrease in apolipoprotein-A1 in 2020 compared to 2019, and 2018 cannot be explained by bias 319 due to gender, age, the cause of liver disease (table1, supplementaryFile3), and the severity 320 of liver diseases (supplementaryFile4). The prevalence of severe cases cannot explain the 321 significant decrease in apolipoprotein-A1 already observed in January 2020. GGT a very 322 sensitive liver biomarkers did not change during the first 3 months (supplementaryFig6). 323

Finally, in these severe liver diseases, haptoglobin should be also significantly decreased 324 (fig2A), which was not observed. 325

In the US-cohort the proportion of sera with NAFLD was increased by 1.8% in 2020 vs 2019 326 (table1). However, after stratification for age and gender, no significant changes were observed 327 for all other biomarkers (supplementaryFig8,supplementaryFig9,supplementaryFig10,  328   supplementaryFig11,supplementaryFile12) . ALT was the only biomarker of the liver tests 329 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. . which increased significantly at the 13 th week of 2020, above the usual mean value observed in 330 2019 (supplementaryFile7). This increase in ALT was not associated with any other changes 331 (supplementaryFig10, supplementaryFig11,supplementaryFig12) . We have no clear 332 explanation. We hypothesize that another confounding factor could be a DILI, including oral 333 acetaminophen or hydroxychloroquine misuse during the pandemic. Such factor could explain 334 an increase in ALT, without increase in haptoglobin, in subjects with mild symptoms. 335

The absence of haptoglobin change (supplementaryFig4) associated with the linear 336 apolipoprotein-A1 decrease (fig1B), has never been described before. It was known that in 337 patients with severe fibrosis these two proteins decrease. 10 It was also known that in severe 338 pneumonia the haptoglobin increase was associated to the apolipoprotein-A1 decrease 339 (supplementaryTable1), as we observed in the cohorts with high prevalence of severe Covid-340 19 (fig2B)(supplementaryFile3). The 30 weeks followup permitted to see the return to normal 341 values of haptoglobin in these cohorts, associated to the decrease of severe Covid-19 cases 342 admissions (supplementaryFig4A). Furthermore, the recovering patients followed by repeated 343 sera in the prospective study, had both a significant increase of apolipoprotein-A1 344 (supplementaryFig15B) and a significant decrease in haptoglobin (supplementaryFig15D), 345 10 days after inclusion. 346

Our results (fig1C) suggest that the spread of the pandemic in the US-cohort would be at least 348 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. . together with the dramatic regression of confirmed cases, still maintained in July. In the US, 355 the apolipoprotein A1 and confirmed cases had the same kinetics with the dramatic increase in 356

April and a plateau in June, still ongoing in July (fig1E). 357

There is a high risk of overestimating the specificity of a test in Covid-19 when the participants 359 enrolled in the studies might not be representative of targeted populations. 1 However, our 360 previous cohorts of patients with severe liver diseases allowed us to identify the major risks of 361 a significant decrease in apolipoprotein-A1 (false positives), mainly due to severe hepatic 362 insufficiency and severe fibrosis. An impact of malnutrition on apolipoprotein-A1 values, was 363 not possible as no changes in weight and height were observed. 364

There is also a high risk of overestimating the sensitivity. 1 It is difficult to confirm the 366 sensitivity for asymptomatic infection, due to the absence of validations of SARS-CoV2-367 antibodies. To validate the sensitivity of apolipoprotein-A1, a large number of asymptomatic 368 "apparently healthy" subjects who are positive for SARS-CoV-2 viral nucleic acid testing is 369 needed. Our patients included with Covid-19 symptoms had a median of 70 years of age and 370 were severe enough to justify admission to hospital, but none of them required mechanical 371 ventilation at admission, 86% survived, only 6% were transferred to the intensive care unit, and 372 9% died (table1). The sensitivity in the prospective part of our study was similar in the 19 373 patients who were negative for viral nucleic acid testing (94.7%) to that in positive patients 374 (89.9%). Thus, a simple measurement of apolipoprotein-A1 could be useful for clinicians due 375 to the high percentage of false negatives in available viral nucleic acid testing. 18 Apolipoprotein-376 A1 or HDL-cholesterol are already being assessed in many large ongoing studies in patients 377 with chronic diseases, which could rapidly validate our results. 378

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. .

The univariate prognostic value of apolipoprotein-A1 was confirmed (fig2D) but to our 380 knowledge, it was the first time that its prognostic value persisted after adjustment by age, a 381 marker of acute inflammation (haptoglobin), a sensitive marker of liver injury (GGT), and a 382 marker of liver fibrosis (A2M). Among patients with recovery, there was a significant increase 383 of apolipoprotein-A1 10 days after admission (supplementaryFig15). Therefore, 384 apolipoprotein-A1 measurement could help for the decision to transfer to ICU. 385

Mechanisms of the early decrease in apolipoprotein-A1 before recognition of the pandemic 386

We never observed such profile of biomarkers in our experience since 2001 with more than 387 three million of FibroTest assessed in liver diseases (supplementaryFile1). 10,12-17 388

Although the mechanisms explaining the decrease in apolipoprotein-A1 in late severe Covid-389 19 pneumonia are known (supplementaryTable1), the reason for the early decrease before the 390 acute phase, when haptoglobin remained normal is unclear. In patients with severe pneumonia, 391 apolipoprotein-A1 decrease was associated with acute inflammation and the "cytokine storm" 392 with an increase in IL6 and acute phase proteins such as CRP and haptoglobin. This dissociation 393 suggests that different mechanisms play a role in the early influence of the SARS-CoV2 virus 394 on the synthesis of apolipoprotein-A1, and the intestine could be more involved than the liver. Apolipoprotein-A1 is released as a free apolipoprotein from the apical side of enterocytes into 404 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. . All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. 0 (0-30) 10 (0-150) 0.14 0.05 (0-30) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 3, 2020. .

MD (Data curation: Equal; Investigation: Equal; Resources: Equal) 62

Resources: Equal; Supervision: Equal; Validation: Equal)

MS (Formal analysis: Equal; Investigation: Equal; Writing -original draft: Equal)

PhD (Funding acquisition: Equal

Resources: Equal; Supervision: Equal; Validation: Equal)

Resources: Equal; Supervision: Equal; Validation: Equal)

Formal analysis: Equal; Supervision: Equal; Validation: Equal

Prediction models for diagnosis and prognosis 418 of Covid-19 infection: systematic review and critical appraisal

Variation in the cholesterol content of the serum in pneumonia

Effect of low high-density lipoprotein levels on mortality 422 of septic patients: A systematic review and meta-analysis of cohort studies

Haptoglobin polymorphism, iron metabolism 425 and mortality in HIV infection

The haptoglobin beta subunit sequesters HMGB1 toxicity 427 in sterile and infectious inflammation

Hypolipidemia is associated with the severity of COVID-19

Cholesterol: A new game player accelerating endothelial 431 injuries caused by SARS-CoV-2?

SARS-CoV-2 productively infects human 434 gut enterocytes

Is SARS-CoV-2 Also an enteric pathogen with potential fecal-oral 437 Transmission? A COVID-19 virological and clinical review

Biochemical markers of liver fibrosis in patients 440 with hepatitis C virus infection: a prospective study

Liver injury in COVID-19: management and challenges

Serum apolipoprotein A1 and haptoglobin, in patients with 444 suspected drug-induced liver injury (DILI) as biomarkers of recovery

Validation of AshTest as a non-invasive alternative 447 to transjugular liver biopsy in patients with suspected severe acute alcoholic hepatitis

Variability in definitions of transaminase upper limit 450 of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic 451 hepatitis C: "APRI c'est fini ?

Candidate biomarkers for the diagnosis 453 and prognosis of drug-induced liver injury: An international collaborative effort

Prevalence of liver fibrosis and risk factors in a general 456 population using non-invasive biomarkers (FibroTest)

Applicability and precautions of use of liver 458 injury biomarker FibroTest. A reappraisal at 7 years of age

Estimating the burden of SARS-CoV-2 in France

Stability issues of RT-PCR testing of SARS-CoV-2 for 462 hospitalized patients clinically diagnosed with COVID-19

Apolipoprotein A-1 deposition in, and 468 release from, the enterocyte brush border: a possible role in transintestinal cholesterol efflux 469 (TICE)?

Responding to Covid-19.A Once-in-a-Century Pandemic?

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity